<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tetracyclines</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tetracyclines</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tetracyclines</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">D Byron May, PharmD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chlortetracycline, the first <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, was discovered in 1948. Since then, multiple additional tetracyclines have been isolated or derived. <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> and <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> are the most frequently prescribed. Subsequent research to find tetracycline analogues led to the development of the glycylcyclines. <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> was the first of this new class of agents and exhibits broad-spectrum antibacterial activity similar to the tetracyclines [<a href="#rid1">1</a>]. Newer agents approved in 2018 include <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a>, <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">sarecycline</a>, and <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>.</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>The tetracyclines enter the bacterial cell wall in two ways: passive diffusion and an energy-dependent active transport system, which is probably mediated in a pH-dependent fashion. Once inside the cell, tetracyclines bind reversibly to the 30S ribosomal subunit at a position that blocks the binding of the aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex. Protein synthesis is ultimately inhibited, leading to a bacteriostatic effect [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3"><span class="h1">RESISTANCE</span><span class="headingEndMark"> — </span>In contrast to many other antibiotics, tetracyclines are infrequently inactivated biologically or altered chemically by resistant bacteria. Resistance to these agents develops primarily by preventing accumulation of the drug inside the cell either by decreasing influx or increasing efflux. Once resistance develops to one of the drugs in this class, it is typically conferred to all tetracyclines.</p><p>However, there are differences in resistance among species of bacteria. Resistance genes to tetracyclines often occur on plasmids or other transferable elements such as transposons [<a href="#rid3">3</a>]. Bacteria carrying a ribosome protection type of resistance gene produce a cytoplasmic protein that interacts with the ribosomes and allows the ribosomes to proceed with protein synthesis even in the presence of high intracellular levels of the drug [<a href="#rid3">3,4</a>].</p><p><a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> has a reduced potential for resistance, as it is not affected by the two major mechanisms of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> resistance: ribosomal protection proteins and many efflux pumps [<a href="#rid5">5</a>]. Thus, tigecycline may have activity against tetracycline-resistant organisms [<a href="#rid6">6,7</a>]. Resistance to tigecycline can occur, however, by overexpression of chromosomally encoded efflux pumps, particularly in <em>Proteus</em> and related genera.</p><p class="headingAnchor" id="H3223468033"><span class="h1">COMMONLY USED AGENTS</span><span class="headingEndMark"> — </span>The commonly used agents include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>. A discussion of newer agents is found below. (See <a class="local">'Newer agents'</a> below.)</p><p><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> is one of the most active tetracyclines and is the most often used clinically since it possesses many advantages over traditional tetracyclines and <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>. Doxycycline can be administered twice daily, has both intravenous (IV) and oral formulations, achieves reasonable concentrations even if administered with food, and is less likely to cause photosensitivity [<a href="#rid8">8</a>]. Doxycycline is the only <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> that should be used for children less than eight years of age since it binds calcium to a lesser extent than tetracycline, which can cause tooth discoloration and bony growth retardation. </p><p>The increase in frequency of multidrug-resistant organisms has led to the resurgence of IV <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> for the treatment of infections caused by these organisms [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Spectrum of activity</span><span class="headingEndMark"> — </span>The antimicrobial activity of all the tetracyclines is essentially the same although some differences in the relative degree of activity against certain pathogens do exist among the various agents  (<a class="graphic graphic_table graphicRef58190" href="/z/d/graphic/58190.html" rel="external">table 1</a>). As an example, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> appears to be the most active of the compounds due to its slight increase in lipid solubility. <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> follows closely behind.</p><p>The tetracyclines are broad-spectrum bacteriostatic antibiotics that are used to treat infection caused by many aerobic gram-positive and gram-negative bacteria. However, they also have activity against many atypical pathogens, including <em>Rickettsia</em> spp, <em>Borrelia</em> spp, <em>Coxiella burnetii</em>, <em>Treponema</em> spp, <em>Chlamydia</em> spp, <em>Mycoplasma pneumoniae</em>, <em>Plasmodium</em> spp, <em>Vibrio cholerae</em>, <em>Vibrio vulnificus</em>, <em>Brucella</em> spp, <em>Calymmatobacterium granulomatis</em>, <em>Leptospira</em>, <em>Borrelia burgdorferi</em>, <em>Borrelia recurrentis</em>, <em>Burkholderia pseudomallei</em>, <em>Mycobacterium marinum</em>, <em>Entamoeba histolytica, Ehrlichia </em>spp, and <em>Anaplasma </em>spp. These drugs have little activity against fungi and viruses [<a href="#rid11">11</a>].</p><p>Against <em>N. gonorrhoeae</em>, the 2006 Gonococcal Isolate Surveillance Project (GISP) report shows that 25.6 percent of isolates collected in 2006 were resistant to penicillin, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, or some combination of those antibiotics [<a href="#rid12">12</a>]. Therefore, use of tetracyclines for the treatment of <em>N. gonorrhoeae</em> in the US is NOT recommended by the CDC.</p><p><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> is effective for patients with nongonococcal urethritis caused by <em>Chlamydia trachomatis</em>; however, recurrent urethritis in patients previously treated with doxycycline may be the result of tetracycline-resistant <em>Ureaplasma urealyticum</em>. Doxycycline is an alternative agent in the treatment of genital chlamydial infections [<a href="#rid13">13</a>].</p><p><a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> has a broader spectrum of activity when compared to the tetracyclines. Tigecycline has activity against gram-positive pathogens including: <em>Enterococcus</em> spp, vancomycin-resistant enterococci (VRE), <em>Listeria</em>, <em>Streptococcus</em> spp, both methicillin-susceptible and -resistant <em>Staphylococcus aureus</em>, and <em>Staphylococcus</em> <em>epidermidis</em>. Its gram-negative activity includes: <em>Acinetobacter baumannii</em>, <em>Citrobacter</em> spp, <em>Enterobacter</em> spp, <em>Escherichia coli</em>, <em>Klebsiella</em> spp, <em>Pasteurella multocida</em>, <em>Serratia marcescens</em>, and <em>Stenotrophomonas maltophilia</em> [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Pharmacodynamics/pharmacokinetics</span><span class="headingEndMark"> — </span>In animal studies, the pharmacokinetic/pharmacodynamic parameter that most closely correlates with the efficacy of tetracyclines is the ratio of the area under the concentration-versus-time (24 hours) curve (AUC) to the minimum inhibitory concentration (MIC). After exposure of <em>S. aureus</em> to the tetracyclines at five times the MIC for two hours, a post-antibiotic effect lasting for three hours has been observed [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Combination of tetracyclines and penicillins</span><span class="headingEndMark"> — </span>A deleterious effect was observed for the combination of a static and cidal antibiotic when chlortetracycline and penicillin were used together for the treatment of pneumococcal meningitis. The combination of the two drugs was inferior to penicillin alone. <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> administered with <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> or <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> may result in diminished bactericidal activity of the penicillin. Thus, combinations of tetracyclines and penicillins should be avoided, if possible.</p><p class="headingAnchor" id="H7"><span class="h3">Absorption of the tetracyclines</span><span class="headingEndMark"> — </span>Absorption of tetracyclines occurs primarily in the proximal small intestine and the stomach. The bioavailability of oral <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> approaches 95 percent (with or without food), with peak serum concentrations seen one to three hours after the dose. By contrast, the bioavailability of oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> is reduced by 50 percent if it is taken with food. The absorption of all tetracyclines can be decreased with the concomitant administration of multivalent cations (ie, aluminum, calcium, iron, magnesium). These cations chelate with the tetracyclines impairing their absorption. Concurrent administration of products containing divalent or trivalent cations should be avoided with all tetracyclines with the possible exception of doxycycline [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Serum concentrations</span><span class="headingEndMark"> — </span>The maximum serum concentration after an intravenous dose of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> occurs within 30 minutes, and after <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, within one hour. Peak concentrations of doxycycline range from 1.5 to 2.5 mcg/mL after a dose of 200 mg orally and 4 to 10 mcg/mL for the same dose administered intravenously. Doxycycline has an apparent volume of distribution of 50 liters and is 90 percent protein bound.</p><p class="headingAnchor" id="H9"><span class="h3">Distribution</span><span class="headingEndMark"> — </span>In general, tetracyclines penetrate into tissues and body fluids well. Among the following agents, the degree of tissue penetration correlates to lipid solubility: <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> &gt; <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> &gt; <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> [<a href="#rid16">16</a>].</p><p>For <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, therapeutic concentrations have been found in the aqueous humor, CSF (11 to 56 percent of serum concentrations), peritoneal fluid, tears, lungs, sinuses, digestive and biliary tracts, kidney, liver, and prostate [<a href="#rid16">16-18</a>]. Doxycycline also distributes into the bone, fat, and muscle at concentrations below plasma levels [<a href="#rid17">17</a>].</p><p><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> distributes well into ascitic fluid, bile, CNS (10 to 26 percent), sinuses, pleural and synovial fluid [<a href="#rid16">16</a>].</p><p><a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> has been found in therapeutic concentrations in the aqueous humor, bile, duodenum, fallopian tubes/ovaries, liver, lung, sinuses, saliva, sputum, tears, and thyroid gland. Minocycline distributes in lower concentrations to the bladder, breast, lymph nodes, prostate, and skin [<a href="#rid16">16,17</a>].</p><p><a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> distributes well into the bile, CSF, and lung. Animal data demonstrate that tigecycline distributes well into bone, bone marrow, spleen, and thyroid [<a href="#rid17">17,19</a>].</p><p>In addition, all the tetracyclines cross the placenta and accumulate in the bone and teeth of the fetus. The tetracyclines are also excreted in breast milk, although complexation with calcium in breast milk limits availability to the breastfed infant [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Routes of elimination</span><span class="headingEndMark"> — </span>The routes of elimination differ among the tetracyclines. The primary route of elimination for <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> is the kidney via glomerular filtration. <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> is primarily eliminated in the intestinal tract, with up to 90 percent of the dose excreted in the feces. Approximately 20 percent of a doxycycline dose is eliminated by glomerular filtration. <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> is eliminated through the feces as unchanged drug.</p><p>Dose adjustment is not necessary for <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> in patients with renal dysfunction, and thus, these are the preferred tetracyclines in this population [<a href="#rid15">15</a>]. Dose adjustment is only required in severe hepatic dysfunction for doxycycline and tigecycline (maintenance dose 25 mg IV every 12 hours) [<a href="#rid5">5</a>]. <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> is metabolized in the liver to at least six inactive metabolites. Only 4 to 9 percent of minocycline is excreted via the kidneys, and fecal concentrations are also minimal. No accumulation of minocycline is seen with hepatic failure. Similar to doxycycline, food has little effect on the absorption of minocycline. The tetracyclines are minimally removed by hemodialysis, peritoneal dialysis, or hemofiltration; therefore, dose adjustments are not necessary in these situations [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H724798944"><span class="h3">Young children</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> antibiotics have been associated with permanent tooth discoloration in children &lt;8 years of age if used repeatedly or for prolonged courses. However, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> binds less readily to calcium than other tetracyclines, and the risk of dental staining with doxycycline is minimal if a short course is administered [<a href="#rid20">20-23</a>]. The American Academy of Pediatrics permits use of doxycycline for ≤21 days in children of all ages [<a href="#rid24">24</a>]. In an observational study of 53 children who received approximately two courses of doxycycline for Rocky Mountain spotted fever before they were eight years old, none developed dental staining in their permanent teeth [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Pregnant or breastfeeding women</span><span class="headingEndMark"> — </span>Tetracyclines cross the placenta and achieve concentrations in umbilical-cord plasma and amniotic fluid that are respectively 60 and 20 percent of levels in the maternal circulation. These levels can cause accumulation in fetal bone and teeth.</p><p>Most tetracyclines are contraindicated in pregnancy because of the risk of hepatotoxicity in the mother [<a href="#rid26">26</a>] and adverse effects on fetal bone and teeth (eg, permanent discoloration of deciduous teeth from in utero exposure in the second and third trimesters [<a href="#rid27">27</a>], incorporation into fetal long tubular bones with transient inhibition of growth [<a href="#rid28">28</a>]). However, these events are extremely rare with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, and observational studies support the relative safety of doxycycline compared with older tetracyclines in both pregnancy and in children [<a href="#rid21">21,29</a>]. As an example, in a systematic review, there was no correlation between the use of doxycycline during pregnancy and teratogenic effects or dental staining in children [<a href="#rid21">21</a>]. Thus, in the setting of certain serious infections (eg, Rocky Mountain spotted fever) when there are no other good alternatives, the benefits of using doxycycline generally outweigh the risks. (See  <a class="medical medical_review" href="/z/d/html/7912.html" rel="external">"Treatment of Rocky Mountain spotted fever", section on 'Pregnant women'</a>.)</p><p>Although tetracyclines are found in high concentrations in human breast milk, concentrations are very low in breastfed infants. This difference is probably due to drug chelation with calcium in breast milk and poor absorption of the chelated complex [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Renal failure</span><span class="headingEndMark"> — </span>These agents, with the possible exception of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, should generally not be used in patients with end-stage kidney disease [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Adverse reactions</span><span class="headingEndMark"> — </span>Tetracyclines are generally safe drugs, but some adverse effects can occur. </p><p>The following provides a brief summary of some of the major adverse effects associated with tetracyclines. These issues are discussed in detail separately. See <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> drug information, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> drug information, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> drug information, <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> drug information, and <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">Demeclocycline</a> drug information.</p><p class="headingAnchor" id="H15"><span class="h3">Gastrointestinal</span><span class="headingEndMark"> — </span>Dose-related gastrointestinal side effects are the most common complaint in patients taking oral tetracyclines and intravenous <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> [<a href="#rid1">1</a>]. These include abdominal discomfort, epigastric pain, nausea, vomiting, and anorexia. Nausea and vomiting have been reported with increased frequency with tigecycline (30 and 20 percent) compared with tetracyclines [<a href="#rid5">5</a>]. Food may decrease these symptoms but also may decrease the absorption of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> by 50 percent. Food does not affect the absorption of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. </p><p>Tetracyclines may alter gut flora to cause large bulky stools and diarrhea. Diarrhea usually subsides once the agent is stopped. A patient with continued diarrhea, fever, and a rising white blood count should be evaluated for antibiotic-associated diarrhea caused by <em>Clostridioides difficile</em>. Esophageal ulcerations and strictures have been reported with tetracyclines but can be prevented by taking the drugs with plenty of water and not before bedtime. (See  <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Allergic and skin reactions</span><span class="headingEndMark"> — </span>Hypersensitivity reactions with tetracyclines are uncommon. If a patient is allergic to one <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, they should be considered allergic to all. Photosensitivity reactions can occur, ranging from a red rash to blistering on areas exposed to the sun. These reactions are most common with <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">demeclocycline</a> but can occur with all tetracyclines. Photosensitivity can be decreased by avoiding direct sunlight or wearing protective clothing and sunscreen [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Teeth and bone</span><span class="headingEndMark"> — </span>Tetracyclines can cause a brown to yellow discoloration of the teeth in children under the age of eight that is sometimes associated with hypoplasia of the enamel. The darkening effect on the permanent teeth appears to be dose-related and does not occur in adults. These agents generally should be avoided in children under the age of eight, but if they must be used, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> may be the preferred agent. Tetracyclines may also deposit in the bone likely due to chelate formation with calcium, thus adding another reason to avoid these agents in children with new bone formation [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Liver and renal</span><span class="headingEndMark"> — </span>Hepatotoxicity with tetracyclines is rare but can be fatal. This adverse effect occurs more commonly with <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> and <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and less often with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid30">30</a>].</p><p>Tetracyclines inhibit protein synthesis and may exacerbate preexisting renal failure by increasing the azotemia from amino acid metabolism. <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">Demeclocycline</a> can cause a nephrogenic diabetes insipidus, a side effect that is used therapeutically to treat the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The use of outdated tetracyclines has been associated with a reversible Fanconi-like syndrome and renal tubular acidosis; however, current formulations, which do not contain citric acid as an excipient, have virtually eliminated this possibility [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat"</a>.)</p><p class="headingAnchor" id="H328328203"><span class="h3">Hematologic</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> has been reported to cause hematologic abnormalities that develop in a dose-dependent manner [<a href="#rid31">31,32</a>]. These typically include low plasma fibrinogen, increased prothrombin time (PT) and activated partial thromboplastin time (APTT), and low platelets. Risk factors include duration of therapy for longer than two weeks, as well as reduced hepatic or renal function (which can result in decreased tigecycline clearance). Although bleeding is rare, patients should have coagulation parameters, including fibrinogen, measured at baseline and weekly during treatment; this is particularly important for those with risk factors for hematologic abnormalities. </p><p>Hematologic side effects of other tetracyclines are uncommon, but may include hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia. </p><p class="headingAnchor" id="H1724385799"><span class="h3">Mortality</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> has been associated with increased mortality when compared with other antibacterial drugs. In September 2010, the US Food and Drug Administration (FDA) issued a safety announcement regarding increased mortality with the use of tigecycline in patients with hospital-acquired pneumonia (HAP) [<a href="#rid33">33</a>]. A 2013 analysis of 10 clinical trials showed an increased risk of death in patients receiving tigecycline for FDA-approved uses, including community-acquired bacterial pneumonia, complicated skin and skin structure infections, and complicated intra-abdominal infections (2.5 versus 1.8 percent, adjusted risk difference 0.6 percent) [<a href="#rid34">34</a>]. The FDA has subsequently added a boxed warning stating that tigecycline should be reserved for use in situations when alternative agents are not suitable [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H19"><span class="h3">Miscellaneous</span><span class="headingEndMark"> — </span>A Jarisch-Herxheimer type reaction (JHR) has occurred in patients being treated for spirochetal infections. Effects include fever, chills, headache, malaise, muscle aches, leukocytosis, and exacerbation of cutaneous lesions. The JHR occurs in 75 to 80 percent of those treated for syphilis, 54 percent of those treated for tick-borne relapsing fever, and 82 percent of those treated for louse-borne relapsing fever. Prevention of the JHR in patients is of limited value; the best results are with the use of tumor necrosis factor (TNF) antibodies and steroids. Pretreatment with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or meptazinol may reduce the symptoms and duration [<a href="#rid36">36</a>].</p><p>Vertigo has been associated with <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and appears to be dose-related. More common in women than men, this may appear during the second or third day of therapy and usually resolves in one to two days after discontinuing the drug. Complaints consist of dizziness, ataxia, nausea, vomiting, and tinnitus.</p><p>Other, less common reactions include minocycline-induced lupus [<a href="#rid37">37-39</a>] and pericardial effusions [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>The absorption of tetracyclines can be impaired by co-administered minerals and antacids (eg, calcium, magnesium, iron), <a class="drug drug_general" data-topicid="10219" href="/z/d/drug information/10219.html" rel="external">lanthanum</a>, and dairy products, including milk. Tetracyclines can interact with oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, beta-lactams, and a variety of other drugs. Specific drug interactions of the tetracyclines and management suggestions may be determined by using the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. </p><p class="headingAnchor" id="H1748841787"><span class="h1">NEWER AGENTS</span><span class="headingEndMark"> — </span>In 2018, several new tetracyclines were approved for use, <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a> [<a href="#rid41">41,42</a>], <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">sarecycline</a> [<a href="#rid43">43</a>], and <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a> [<a href="#rid44">44</a>]. Eravacycline and omadacycline may have a role in the treatment of certain drug-resistant organisms.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">Eravacycline</a> – Eravacycline is an intravenous agent that has been found to be effective for the treatment of complicated intra-abdominal infections in adults caused by <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, <em>Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides </em>species<em>, </em>and<em> Parabacteroides distasonis </em>[<a href="#rid41">41,42</a>]. Eravacycline has<em> </em>been approved for use by the US Food and Drug Administration and the European Medicines Agency. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">Eravacycline</a> resulted in similar clinical cure rates as carbapenems for complicated intra-abdominal infections, even among patients with infections caused by extended-spectrum beta-lactamase (ESBL)-producing organisms [<a href="#rid45">45</a>]. In addition, it appears to have activity against carbapenem-resistant <em>Acinetobacter baumannii </em>[<a href="#rid46">46-48</a>]<em>.</em> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">Omadacycline</a> – Omadacycline is available in both oral and intravenous formulations [<a href="#rid44">44,49</a>]. It is indicated for the treatment of adults with community-acquired bacterial pneumonia caused by <em>S. pneumoniae, S. aureus </em>(methicillin-susceptible isolates),<em> Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, </em>and<em> Chlamydophila pneumoniae</em>. In a clinical trial that included 774 adults, omadacycline was noninferior to <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> for the treatment of community-acquired bacterial pneumonia [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">In addition, <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a> can be used to treat acute bacterial skin and skin structure infections in adults caused by <em>S. aureus </em>(methicillin-susceptible and -resistant isolates),<em> Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus </em>group<em> </em>(includes<em> S. anginosus, S. intermedius,</em> and<em> S. constellatus), Enterococcus faecalis, Enterobacter cloacae, </em>and<em> K. pneumoniae</em>. Data suggest that omadacycline is as effective as <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> in this setting [<a href="#rid51">51,52</a>]. </p><p></p><p class="bulletIndent1">More detailed information on the use of <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a> for the treatment of community-acquired pneumonia and skin and skin structure infections is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'New antimicrobial agents'</a> and  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections", section on 'Omadacycline'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">Sarecycline</a> – Sarecycline is an oral agent approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age or older [<a href="#rid43">43</a>]. </p><p></p><p>Adverse reactions and contraindications for these new agents are similar to those for other tetracyclines. (See <a class="local">'Adverse reactions'</a> above.)</p><p class="headingAnchor" id="H9761634"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Tetracyclines inhibit bacterial protein synthesis by binding reversibly to the 30S ribosomal subunit. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased accumulation of drug within bacteria leads to resistance; drug uptake is affected by decreasing influx or increasing efflux. Plasmid-encoded resistance proteins can also affect <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> binding the ribosome. (See <a class="local">'Resistance'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The tetracyclines are broad-spectrum bacteriostatic antibiotics with activity against many aerobic gram-positive and gram-negative bacteria and atypical pathogens, such as mycoplasma and chlamydia. (See <a class="local">'Spectrum of activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absorption of tetracyclines occurs primarily in the proximal small intestine and the stomach with good distribution into tissues and body fluids. (See <a class="local">'Pharmacodynamics/pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tetracyclines have been associated with permanent tooth discoloration in children &lt;8 years of age if used repeatedly or for prolonged courses, and with accumulation in fetal bones and teeth when administered to pregnant women. However, in contrast to older tetracyclines, the risk of dental staining with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is minimal if a short course is administered, and doxycycline can be used for ≤21 days in children of all ages. In addition, doxycycline has not been correlated with teratogenic effects during pregnancy and is a treatment option when other agents appear less effective. (See <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tetracyclines are generally safe; the most common adverse events are related to gastrointestinal symptoms (eg, epigastric discomfort and nausea). (See <a class="local">'Adverse reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2018, several new tetracyclines were approved for use (<a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a>, <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">sarecycline</a>, and <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>). Eravacycline and omadacycline may have a role in the treatment of certain drug-resistant organisms. (See <a class="local">'Newer agents'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43:518.</a></li><li><a class="nounderline abstract_t">Schnappinger D, Hillen W. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol 1996; 165:359.</a></li><li><a class="nounderline abstract_t">Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992; 5:387.</a></li><li><a class="nounderline abstract_t">Roberts MC. Tetracycline therapy: update. Clin Infect Dis 2003; 36:462.</a></li><li><a class="nounderline abstract_t">Tigecycline (tygacil). Med Lett Drugs Ther 2005; 47:73.</a></li><li><a class="nounderline abstract_t">Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63.</a></li><li><a class="nounderline abstract_t">Wyeth antibiotic Tygacil approved for broad-spectrum, early use. "The Pink Sheet" 2005; 67:12.</a></li><li class="breakAll">Perdue, BE, Standiford, HC. Tetracyclines. In: Antimicrobial Therapy and Vaccines, Yu, VL, Merigan, TC, Barriere, SL (Eds), Williams and Wilkins, Baltimore 1999. p.981.</li><li><a class="nounderline abstract_t">Colton B, McConeghy KW, Schreckenberger PC, Danziger LH. I.V. minocycline revisited for infections caused by multidrug-resistant organisms. Am J Health Syst Pharm 2016; 73:279.</a></li><li><a class="nounderline abstract_t">Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review. Infect Dis Ther 2017; 6:199.</a></li><li><a class="nounderline abstract_t">Klein NC, Cunha BA. Tetracyclines. Med Clin North Am 1995; 79:789.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2006. Atlanta, GA: U.S. Department of Health and Human Services, November 2007.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Nonfatal, unintentional medication exposures among young children--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1.</a></li><li><a class="nounderline abstract_t">Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15:355.</a></li><li class="breakAll">Mandell, GL, Bennett, JE, Dolin, R, et al. Principles and Practices of Infectious Diseases, 6th ed, Churchill Livingstone, Philadelphia 2005.</li><li><a class="nounderline abstract_t">Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58:256.</a></li><li><a class="nounderline abstract_t">Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985; 28:347.</a></li><li><a class="nounderline abstract_t">MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008; 62 Suppl 1:i11.</a></li><li><a class="nounderline abstract_t">Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998; 17:429.</a></li><li><a class="nounderline abstract_t">Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf 2016; 15:367.</a></li><li><a class="nounderline abstract_t">Pöyhönen H, Nurmi M, Peltola V, et al. Dental staining after doxycycline use in children. J Antimicrob Chemother 2017; 72:2887.</a></li><li><a class="nounderline abstract_t">Volovitz B, Shkap R, Amir J, et al. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila) 2007; 46:121.</a></li><li class="breakAll">American Academy of Pediatrics. Tetracyclines. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.905.</li><li><a class="nounderline abstract_t">Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015; 166:1246.</a></li><li><a class="nounderline abstract_t">Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Vennila V, Madhu V, Rajesh R, et al. Tetracycline-induced discoloration of deciduous teeth: case series. J Int Oral Health 2014; 6:115.</a></li><li><a class="nounderline abstract_t">Cohlan SQ, Bevelander G, Tiamsic T. Growth Inhibition of Prematures Receiving Tetracycline. Am J Dis Child 1963; 105:453.</a></li><li><a class="nounderline abstract_t">Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol 2009; 23:18.</a></li><li><a class="nounderline abstract_t">Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007; 32:483.</a></li><li><a class="nounderline abstract_t">Cui N, Cai H, Li Z, et al. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm 2019; 41:1408.</a></li><li><a class="nounderline abstract_t">Hakeam HA, Al Duhailib Z. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm 2020; 42:846.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA drug safety communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections . http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed on September 02, 2010).</li><li class="breakAll">US Food and Drug Administration. Tygacil: Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s026s031lbl.pdf (Accessed on November 30, 2018).</li><li class="breakAll">US Food and Drug Administration (FDA). FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm (Accessed on May 05, 2015).</li><li><a class="nounderline abstract_t">Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005; 30:291.</a></li><li><a class="nounderline abstract_t">Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A systematic review. Dermatology 2000; 200:223.</a></li><li><a class="nounderline abstract_t">Colmegna I, Perandones CE, Chaves JG. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol 2000; 27:1567.</a></li><li><a class="nounderline abstract_t">Lawson TM, Amos N, Bulgen D, Williams BD. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001; 40:329.</a></li><li><a class="nounderline abstract_t">Christe C, Ricou F, Stoller R, Vogt N. Minocycline-induced pericardial effusion. Ann Pharmacother 2000; 34:875.</a></li><li class="breakAll">European Medicines Agency. Xerava: product information. European Medicines Agency;
2018. https://www.ema.europa.eu/en/medicines/human/EPAR/xerava (Accessed on November 14, 2018).</li><li class="breakAll">U.S. Food and Drug Administration. XERAVA (eravacycline) Full Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf; (Accessed on November 14, 2018).</li><li class="breakAll">Sarecycline package insert. 1.U.S. Food and Drug Administration. October 1st, 2018. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm592464.htm (Accessed on November 14, 2018).</li><li class="breakAll">Omadacycline package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf (Accessed on November 14, 2018).</li><li><a class="nounderline abstract_t">Solomkin J, Evans D, Slepavicius A, et al. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. JAMA Surg 2017; 152:224.</a></li><li><a class="nounderline abstract_t">Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 2018; 51:62.</a></li><li><a class="nounderline abstract_t">Koulenti D, Song A, Ellingboe A, et al. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline? Int J Antimicrob Agents 2019; 53:211.</a></li><li class="breakAll">Newman J, Izmailyan S, Fyfe C, Tsai, L. Microbiological Efficacy of Eravacycline against Enterobacteriaceae And Acinetobacter, Including Mdr Isolates: A Pooled Analysis from Ignite1 and Ignite4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection. Presented at ASM Microbe 2018, June 7-11 2018, Atlanta GA.</li><li><a class="nounderline abstract_t">Barber KE, Bell AM, Wingler MJB, et al. Omadacycline Enters the Ring: A New Antimicrobial Contender. Pharmacotherapy 2018; 38:1194.</a></li><li><a class="nounderline abstract_t">Stets R, Popescu M, Gonong JR, et al. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med 2019; 380:517.</a></li><li><a class="nounderline abstract_t">Noel GJ, Draper MP, Hait H, et al. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:5650.</a></li><li><a class="nounderline abstract_t">O'Riordan W, Green S, Overcash JS, et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med 2019; 380:528.</a></li></ol></div><div id="topicVersionRevision">Topic 494 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16838243" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tigecycline: a critical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8661929" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tetracyclines: antibiotic action, uptake, and resistance mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1423217" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12567304" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tetracycline therapy: update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151368" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tigecycline (tygacil).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723559" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The glycylcyclines: a comparative review with the tetracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Wyeth antibiotic Tygacil approved for broad-spectrum, early use</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Wyeth antibiotic Tygacil approved for broad-spectrum, early use</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26896499" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : I.V. minocycline revisited for infections caused by multidrug-resistant organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28357705" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791423" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tetracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791423" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tetracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16410759" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nonfatal, unintentional medication exposures among young children--United States, 2001-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9455502" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3072140" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical pharmacokinetics of doxycycline and minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3072140" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical pharmacokinetics of doxycycline and minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16816396" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3834836" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684702" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tigecycline pharmacokinetic/pharmacodynamic update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613662" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Doxycycline and staining of permanent teeth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26680308" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091225" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dental staining after doxycycline use in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325084" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Absence of tooth staining with doxycycline treatment in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325084" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Absence of tooth staining with doxycycline treatment in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794784" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572105" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25083046" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tetracycline-induced discoloration of deciduous teeth: case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Growth Inhibition of Prematures Receiving Tetracycline</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228311" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875115" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31713108" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tigecycline-induced coagulopathy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219684" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tigecycline-induced coagulopathy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219684" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tigecycline-induced coagulopathy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219684" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tigecycline-induced coagulopathy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219684" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tigecycline-induced coagulopathy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15896248" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10828631" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Minocycline-induced lupus. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852297" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Minocycline induced lupus and autoimmune hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11285382" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Minocycline-induced lupus: clinical features and response to rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928400" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Minocycline-induced pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928400" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Minocycline-induced pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928400" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Minocycline-induced pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928400" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Minocycline-induced pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928400" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Minocycline-induced pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27851857" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705668" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30394301" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30394301" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30290000" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Omadacycline Enters the Ring: A New Antimicrobial Contender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30726692" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Omadacycline for Community-Acquired Bacterial Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22908151" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30726689" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
